Benjamin B Albert1, José G B Derraik1,2, Yin-Yin Xia3, Tom Norris4, Ting Zhang5, Ting-Li Han5,6, Chen Chang5,6, Angela Rowan7, Sophie Gallier7, Renato T Souza8, Judith J Hammond9, Wei Zhou10, Hua Zhang5,6, Hong-Bo Qi5,6, Philip N Baker4,5,6. 1. Liggins Institute, University of Auckland, Auckland, New Zealand. 2. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 3. School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, China. 4. College of Life Sciences, University of Leicester, Leicester, United Kingdom. 5. Department of Obstetrics and Gynaecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 6. Canada-China-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing, China. 7. Fonterra Co-operative Group Ltd, Palmerston North, New Zealand. 8. Department of Obstetrics and Gynaecology, University of Campinas, Campinas, Brazil. 9. Auckland UniServices Ltd, Auckland, New Zealand. 10. Department of Obstetrics, Chongqing Health Centre for Women and Children, Chongqing, China.
Abstract
BACKGROUND: Gangliosides are a class of sphingolipids that are present in the cell membranes of vertebrates. Gangliosides influence a broad range of cellular processes through effects on signal transduction, being found abundantly in the brain, and having a role in neurodevelopment. OBJECTIVE: We aimed to assess the effects of maternal daily consumption of ganglioside-enriched milk vs non-enriched milk and a non-supplemented group of pregnant women on maternal ganglioside levels and pregnancy outcomes. DESIGN: Double-blind parallel randomized controlled trial. METHODS:1,500 women aged 20-40 years were recruited in Chongqing (China) between 11 and 14 weeks of a singleton pregnancy, and randomized into three groups: Control-received standard powdered milk formulation (≥4 mg gangliosides/day); Complex milk lipid-enhanced (CML-E) group-same formulation enriched with complex milk lipids (≥8 mg gangliosides/day) from milk fat globule membrane; Reference-received no milk. Serum ganglioside levels were measured in a randomly selected subsample of 250 women per group. RESULTS: CML-E milk was associated with marginally greater total gangliosides levels in maternal serum compared to Control (13.02 vs 12.69 μg/ml; p = 0.034) but not to Reference group. CML-E milk did not affect cord blood ganglioside levels. Among the 1500 women, CML-E milk consumption was associated with a lower rate of gestational diabetes mellitus than control milk [relative risk 0.80 (95% CI 0.64, 0.99)], but which was not different to the Reference group. CML-E milk supplementation had no other effects on maternal or newborn health. CONCLUSIONS: Maternal supplementation with milk fat globule membrane, as a source of gangliosides, was not associated with any adverse health outcomes, and did not increase serum gangliosides compared with the non-supplemented reference group. TRIAL REGISTRATION: Chinese Clinical Trial Register (ChiCTR-IOR-16007700). CLINICAL TRIAL REGISTRATION: ChiCTR-IOR-16007700; www.chictr.org.cn/showprojen.aspx?proj=12972.
RCT Entities:
BACKGROUND:Gangliosides are a class of sphingolipids that are present in the cell membranes of vertebrates. Gangliosides influence a broad range of cellular processes through effects on signal transduction, being found abundantly in the brain, and having a role in neurodevelopment. OBJECTIVE: We aimed to assess the effects of maternal daily consumption of ganglioside-enriched milk vs non-enriched milk and a non-supplemented group of pregnant women on maternal ganglioside levels and pregnancy outcomes. DESIGN: Double-blind parallel randomized controlled trial. METHODS: 1,500 women aged 20-40 years were recruited in Chongqing (China) between 11 and 14 weeks of a singleton pregnancy, and randomized into three groups: Control-received standard powdered milk formulation (≥4 mg gangliosides/day); Complex milk lipid-enhanced (CML-E) group-same formulation enriched with complex milk lipids (≥8 mg gangliosides/day) from milk fat globule membrane; Reference-received no milk. Serum ganglioside levels were measured in a randomly selected subsample of 250 women per group. RESULTS:CML-E milk was associated with marginally greater total gangliosides levels in maternal serum compared to Control (13.02 vs 12.69 μg/ml; p = 0.034) but not to Reference group. CML-E milk did not affect cord blood ganglioside levels. Among the 1500 women, CML-E milk consumption was associated with a lower rate of gestational diabetes mellitus than control milk [relative risk 0.80 (95% CI 0.64, 0.99)], but which was not different to the Reference group. CML-E milk supplementation had no other effects on maternal or newborn health. CONCLUSIONS: Maternal supplementation with milk fat globule membrane, as a source of gangliosides, was not associated with any adverse health outcomes, and did not increase serum gangliosides compared with the non-supplemented reference group. TRIAL REGISTRATION: Chinese Clinical Trial Register (ChiCTR-IOR-16007700). CLINICAL TRIAL REGISTRATION: ChiCTR-IOR-16007700; www.chictr.org.cn/showprojen.aspx?proj=12972.
Authors: Tadashi Yamashita; Akira Hashiramoto; Martin Haluzik; Hiroki Mizukami; Shoshannah Beck; Aaron Norton; Mari Kono; Shuichi Tsuji; Jose Luis Daniotti; Norbert Werth; Roger Sandhoff; Konrad Sandhoff; Richard L Proia Journal: Proc Natl Acad Sci U S A Date: 2003-03-10 Impact factor: 11.205
Authors: Jian Guan; Alastair MacGibbon; Rong Zhang; Douglas M Elliffe; Steve Moon; Dong-Xu Liu Journal: Nutr Neurosci Date: 2013-11-20 Impact factor: 4.994
Authors: Mark H Vickers; Jian Guan; Malin Gustavsson; Christian U Krägeloh; Bernhard H Breier; Michael Davison; Bertram Fong; Carmen Norris; Paul McJarrow; Steve C Hodgkinson Journal: Nutr Res Date: 2009-06 Impact factor: 3.315
Authors: Jamie V de Seymour; Kathryn L Beck; Cathryn A Conlon; Mary Beatrix Jones; John Colombo; Yin-Yin Xia; Ting-Li Han; Hong-Bo Qi; Hua Zhang; Philip N Baker Journal: Front Nutr Date: 2022-04-22